BioSpace News Archive

Daiichi Sankyo and AstraZeneca have received notification of acceptance by the U.S. Food and Drug Administration of the supplemental Biologics License Application of ENHERTU® for the treatment of adult patients with unresectable or metastatic HER2 low 1+ or IHC 2+/in-situ hybridization -negative) breast cancer who have received a prior therapy in the metastatic setting.

G1 Therapeutics, Inc., a commercial-stage oncology company, announced the appointment of Norman E. “Ned” Sharpless, M.D., to its Board of Directors.

Nanoscope Therapeutics Inc. today announced that the first patient has been dosed in a Phase 2 trial of its Multi-Characteristic Opsin (MCO-010) ambient-light activatable optogenetic monotherapy for Stargardt disease.

Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, will release its second-quarter 2022 financial results on Thursday, Aug. 4, 2022.

Precision BioSciences, Inc., a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, announced that, on July 19, 2022, the Compensation Committee of Precision’s Board of Directors approved the grant of inducement awards to new employees under the Precision BioSciences, Inc. 2021 Employment Inducement Incentive Award Plan.

ENHERTU ® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US for patients with HER2-low metastatic breast cancer.

Komodo Deepens Its Commitment To Illuminate Critical Insights for Public Health and Industry Leaders to Better Address Gaps in Care for Colorectal Cancer Community.

Generate Biomedicines today announced that Jason Silvers, M.D., has been named the company’s Chief Financial Officer, overseeing all financial matters as the company advances into its next stage of growth.

Castle Biosciences surpasses 100,000 orders for its flagship risk-stratification test designed to help guide risk-appropriate treatment decisions for patients diagnosed with cutaneous melanoma.

InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today provided an update on its Phase 2 clinical trial using investigational drug INM-755 cannabinol (“CBN”) cream for the treatment of patients with epidermolysis bullosa (“EB”).